Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy, MK-8931

Dateline City: WHITEHOUSE STATION, N.J. Data Monitoring Committee recommends continuation of Phase II/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Justine O’Malley, 908-423-2021orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News Source Type: news
More News: Merck | Pharmaceuticals | Study